Singular Genomics Systems
Our mission is to accelerate genomics for the advancement of science and medicine.
We are a life science technology company that is leveraging novel next generation sequencing (NGS) and multiomics technologies to build products that empower researchers and clinicians. We developed a unique and proprietary NGS technology, which we refer to as our Sequencing Engine. This Sequencing Engine is the foundational platform technology that forms the basis of our products in development and our core product tenets: accuracy, speed, flexibility and scale.
We are currently developing two integrated solutions that are purpose built to target specific applications in which these core product tenets matter most. Our first integrated solution is targeted at the NGS market and comprises an instrument (the G4 Instrument) and an associated menu of consumable kits, which we refer to collectively as our G4 Integrated Solution. The G4 Instrument is a benchtop next generation sequencer designed to produce fast and accurate genetic sequencing results. The integrated purpose built kits that run on the G4 Instrument address specific applications in fast-growing markets, including oncology and immune profiling. We have completed our beta pilot program (which is our first external third-party evaluation) and anticipate initiating an early access program followed by a commercial launch of the G4 Integrated Solution by the end of 2021, with intentions for units to ship in the first half of 2022.
Our second integrated solution in development comprises an instrument (the PX Instrument) and an associated menu of consumable kits, which we refer to collectively as our PX Integrated Solution. Leveraging sequencing as a universal readout, the PX Integrated Solution combines single cell analysis, spatial analysis, genomics and proteomics in one integrated instrument providing a versatile multiomics solution. We anticipate commercial launch of the PX Integrated Solution in 2023.
(Note: Singular Genomics Systems, Inc. upsized its IPO at pricing on May 26, 2021, to 10.2 million shares, up from 8.5 million shares in the prospectus, at $22 – the top of its $20-to-$22 range – to raise $224.4 million.)
|Industry:||LABORATORY ANALYTICAL INSTRUMENTS|
|Address||10931 N. Torrey Pines Road Suite #100 La Jolla, CA 92037|
|Phone Number||(858) 333-7830|
|View Prospectus:||Singular Genomics Systems|
|Revenues||$0 mil (last 12 months)|
|Net Income||$-27.95 mil (last 12 months)|
|Price range||$22.00 - $22.00|
|Est. $ Volume||$224.4 mil|
|Manager / Joint Managers||J.P. Morgan/ Goldman Sachs/ BofA Securities/ Cowen and Company/ UBS Investment Bank|
|Expected To Trade:||5/27/2021|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|